Related references
Note: Only part of the references are listed.Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
Andreas Kerschbaumer et al.
ANNALS OF THE RHEUMATIC DISEASES (2023)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2023)
Incidence, Risk Factors, and Mortality of Clinical and Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Population-Based Cohort
Bilal F. Samhouri et al.
ARTHRITIS CARE & RESEARCH (2022)
Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study
Kosuke Ebina et al.
SCIENTIFIC REPORTS (2022)
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration
Kim Lauper et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial
Rene Westhovens et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
Bernard Combe et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
The Association of Disease Activity and Estimated GFR in Patients With Rheumatoid Arthritis: Findings From the ANSWER Study
Akira Onishi et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2021)
Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study
Sadao Jinno et al.
ARTHRITIS RESEARCH & THERAPY (2021)
Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naive patients with rheumatoid arthritis
Kim Lauper et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)
Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis
Andreas Kerschbaumer et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Rheumatoid arthritis in the elderly: Characteristics and treatment considerations
Lina Serhal et al.
AUTOIMMUNITY REVIEWS (2020)
Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland
A. Finckh et al.
RMD OPEN (2020)
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
Josef S. Smolen et al.
LANCET (2019)
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial
Roy Fleischmann et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017
Saeid Safiri et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Avoiding pitfalls when combining multiple imputation and propensity scores
Emily Granger et al.
STATISTICS IN MEDICINE (2019)
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
Alison O'Mahony et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
Roy Fleischmann et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
Peter C. Austin et al.
STATISTICS IN MEDICINE (2015)
Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
Paul Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
Eun Bong Lee et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
Paul Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Cem Gabay et al.
LANCET (2013)
A tutorial on propensity score estimation for multiple treatments using generalized boosted models
Daniel F. McCaffrey et al.
STATISTICS IN MEDICINE (2013)
Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
Moetaza M. Soliman et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
Daniel Aletaha et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Use of Stabilized Inverse Propensity Scores as Weights to Directly Estimate Relative Risk and Its Confidence Intervals
Stanley Xu et al.
VALUE IN HEALTH (2010)
Competing Risk Regression Models for Epidemiologic Data
Bryan Lau et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2009)
Utilization Trends of Tumor Necrosis Factor Inhibitors Among Patients with Rheumatoid Arthritis in a United States Observational Cohort Study
Susan J. Lee et al.
JOURNAL OF RHEUMATOLOGY (2009)
Discontinuation of Methotrexate Therapy in Older Patients with Newly Diagnosed Rheumatoid Arthritis Analysis of Administrative Health Databases in Quebec, Canada
Sasha Bernatsky et al.
DRUGS & AGING (2008)
Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD
Luis F. Ramos et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
FC Breedveld et al.
ARTHRITIS AND RHEUMATISM (2006)
Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
D Aletaha et al.
ARTHRITIS RESEARCH & THERAPY (2005)
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
L Klareskog et al.
LANCET (2004)
Marginal structural models and causal inference in epidemiology
JM Robins et al.
EPIDEMIOLOGY (2000)
The role of the propensity score in estimating dose-response functions
GW Imbens
BIOMETRIKA (2000)
Share Paper
